Skip to main content
. Author manuscript; available in PMC: 2013 May 30.
Published in final edited form as: Psychiatry Res. 2012 Mar 13;197(3):206–211. doi: 10.1016/j.psychres.2012.01.017

Table 2.

Positive and Negative Syndrome Scale (PANSS) Symptoms at Time 1 and Time 2 by Comorbid Diagnosis and Gender.

Schizophrenia Only
Schizophrenia + Non-Panic Anxiety
Schizophrenia + Panic
Comorbid Diagnosis Gender
Males Females Males Females Males Females






M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) F P F P
Time 1 (At Admission)
Positive Factor 11.6 (5.0) 13.0 (4.5) 11.4 (4.5) 14.2 (4.9) 12.1 (4.6) 11.9 (3.0) 0.25
0.783
2.40 0.124
Negative Factor 20.0 (6.6) 15.3 (5.6) 21.2 (9.0) 18.8 (7.2) 19.1 (7.6) 16.5 (4.5) 1.54
0.218
4.82 0.030*
Activation Factor 9.8 (4.2) 9.6 (5.0) 10.3 (4.4) 11.2 (5.1) 9.9 (3.9) 10.9 (4.6) 0.80
0.453
0.57 0.451
Dysthymi a Factor 9.6 (4.7)a 10.0 (2.9)a 9.3 (3.4)a 10.5 (4.2)a 12.3 (2.5)b 10.7 (4.1)b 1.68
0.190
0.00 0.955
Autism Factor 13.0 (4.6) 13.0 (5.1) 13.4 (5.2) 13.8 (3.6) 12.1 (4.5) 11.3 (3.5) 1.43
0.244
0.01 0.929
n = 45 n = 21 n = 16 n = 17 n = 15 n = 10
Time 2 (At Fixed Dose Treatment)
Positive Factor 10.8 (5.1) 12.2 (4.8) 10.5 (5.0) 11.0 (5.4) 11.0 (4.8) 10.5 (4.1) 0.47
0.624
0.55 0.581
Negative Factor 18.6 (7.3) 16.3 (6.2) 20.0 (6.0) 20.0 (7.5) 19.2 (7.0) 18.8 (6.7) 2.36
0.097
0.46 0.630
Activation Factor 8.7 (4.1) 9.7 (4.4) 9.9 (3.2) 11.1 (5.7) 8.9 (2.9) 10.7 (5.2) 1.53
0.219
0.08 0.925
Dysthymia Factor 8.1 (3.5)a 8.7 (3.5)a 8.2 (3.4)a 9.6 (4.2)a 11.4 (5.2)b 11.4 (4.2)b 7.36
0.001***
0.43 0.650
Autism Factor 11.8 (4.3) 12.6 (5.0) 12.0 (4.1) 13.1 (4.5) 11.9 (4.9) 11.3 (5.6) 0.46
0.632
0.34 0.714
n = 93 n = 37 n = 24 n = 22 n = 21 n = 12

Note. Schizophrenia diagnosis of participant (i.e., schizophrenia or schizoaffective disorder) was entered as a covariate but was insignificant in all analyses. There were no significant interactions between the Comorbid Diagnosis and Gender factors.

*

P < 0.05.

**

P < 0.01.

***

P < 0.001.

a and b superscripts are used to denote statistically different diagnostic groups (P < 0.05), where applicable, as confirmed by LSD post-hoc analysis.